{"id":"rgn-259","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RGN-259 uses a patient's own stem cells to generate new retinal cells, which can potentially replace damaged or diseased cells in the retina. This approach has shown promise in preclinical studies for treating various retinal diseases.","oneSentence":"RGN-259 is a stem cell therapy that aims to promote retinal regeneration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:05.319Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of retinitis pigmentosa"}]},"trialDetails":[{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT02600429","phase":"PHASE3","title":"Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1","status":"TERMINATED","sponsor":"ReGenTree, LLC","startDate":"2015-09-17","conditions":"Neurotrophic Keratopathy","enrollment":18},{"nctId":"NCT03937882","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2019-05-24","conditions":"Dry Eye Syndromes, Dry Eye","enrollment":700},{"nctId":"NCT02974907","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2016-11","conditions":"Dry Eye Syndrome","enrollment":601},{"nctId":"NCT02597803","phase":"PHASE2, PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2015-09","conditions":"Dry Eye Syndrome","enrollment":317},{"nctId":"NCT01393132","phase":"PHASE2","title":"Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye","status":"COMPLETED","sponsor":"Michigan Cornea Consultants, PC","startDate":"2011-03","conditions":"Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease","enrollment":9},{"nctId":"NCT01387347","phase":"PHASE2","title":"Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2011-08","conditions":"Dry Eye Syndrome, Dry Eye","enrollment":72},{"nctId":"NCT00598871","phase":"PHASE2","title":"A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds","status":"TERMINATED","sponsor":"ReGenTree, LLC","startDate":"2007-12","conditions":"Diabetes","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tβ4","Thymosin Beta 4","Timbetasin"],"phase":"phase_3","status":"active","brandName":"RGN-259","genericName":"RGN-259","companyName":"ReGenTree, LLC","companyId":"regentree-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RGN-259 is a stem cell therapy that aims to promote retinal regeneration. Used for Treatment of retinitis pigmentosa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}